


RECEIVED Receipt

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE Docket 935.38812X00

Applicants: BENAROUS, et al.
Serial No: 09/601,168
Filed: July 28, 2000
Title: PROTEIN HUMAINE BETA-TRCP
Group: 1645



RECEIVED

FEB 13 2001

REQUEST FOR CORRECTED FILING RECEIPT

TECH CENTER 1600/2900

Assistant Commissioner
for Patents
Washington, D.C. 20231

November 21, 2000


Sir:

Attached hereto is the Official Filing Receipt for the above-identified application, wherein it is noted that the customer number 020457 of the law firm is missing from above the correspondence address, also the total number of drawings, claims and independent claims are incorrect.

Accordingly, it is respectfully requested that a corrected filing receipt be issued showing customer number 020457 above the correspondence address, also the total number of drawings to be THIRTEEN(13); the total number of claims to be THIRTY-SIX(36); and the total number of independent claims to be TWO(2).

Respectfully submitted,

ANTONELLI, TERRY, STOUT & KRAUS, LLP


James N. Dresser
Registration No. 22,973

JND/sab
(703) 312-6600
Attachments

FILING RECEIPT



OC00000005340874

UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark OfficeAddress: ASSISTANT SECRETARY AND
COMMISSIONER OF PATENT AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/601,168 ✓	07/28/2000 ✓	1645	1128	935.38812X00	1213	136	12

040457
ANTONELLI TERRY STOUT & KRAUS
1300 NORTH SEVENTEENTH STREET
SUITE 1800
ARLINGTON, VA 22209



Date Mailed: 08/21/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

RICHARD BENAROUS, PARIS, FRANCE; ✓
FLORENCE MARGOTTIN, PARIS, FRANCE; ✓
HERVE DURAND, BOURAY/JUINE, FRANCE; ✓
FERNANDO ARENZANA SEISDEDOS, MEUDON, FRANCE; ✓
MATHIAS KROLL, PARIS, FRANCE; ✓
JEAN-PAUL CONCORDET, VINCENNES, FRANCE; ✓

RECEIVED

FEB 13 2001

Continuing Data as Claimed by Applicant

THIS APPLICATION IS A 371 OF PCT/FR99/00196 01/29/1999 ✓

TECH CENTER 1600/2000

Foreign Applications

FRANCE 98/01100 01/30/1998 ✓
FRANCE 98/15545 12/09/1998 ✓

If Required, Foreign Filing License Granted 08/21/2000

Title

PROTEIN HUMAINE BETA-TRCP ✓

Preliminary Class

435

Data entry by : BARRETO, NGA

Team : OIPE

Date: 08/21/2000

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231



UNITED STATES PATENT AND TRADEMARK OFFICE

FILE COPY

 COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
 www.uspto.gov


Bib Data Sheet

SERIAL NUMBER 09/601,168	FILING DATE 07/28/2000 RULE -	CLASS 435	GROUP ART UNIT 4645 1653	ATTORNEY DOCKET NO. 935.38812X00
------------------------------------	---	---------------------	---------------------------------------	--

APPLICANTS

RICHARD BENAROUS, PARIS, FRANCE;
 FLORENCE MARGOTTIN, PARIS, FRANCE;
 HERVE DURAND, BOURAY/JUINE, FRANCE;
 FERNANDO ARENZANA SEISDEDOS, MEUDON, FRANCE;
 MATHIAS KROLL, PARIS, FRANCE;
 JEAN-PAUL CONCORDET, VINCENNES, FRANCE;

RECEIVED

FEB 13 2001

TECH CENTER 1600/2900

** CONTINUING DATA *****

THIS APPLICATION IS A 371 OF PCT/FR99/00196 01/29/1999

** FOREIGN APPLICATIONS *****

FRANCE 98/01100 01/30/1998
 FRANCE 98/15545 12/09/1998

IF REQUIRED, FOREIGN FILING LICENSE
 GRANTED ** 08/21/2000

Foreign Priority claimed <input checked="" type="checkbox"/> yes <input type="checkbox"/> no	STATE OR COUNTRY FRANCE	SHEETS DRAWING 12	TOTAL CLAIMS 7	INDEPENDENT CLAIMS 1
35 USC 119 (a-d) conditions met <input checked="" type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> Met after Allowance				
Verified and Acknowledged Examiner's Signature: <i>[Signature]</i> Initials: <i>[Initials]</i>				

ADDRESS

020457

TITLE

PROTEIN HUMAINE BETA-TRCP

FILING FEE RECEIVED
1128

FEES: Authority has been given in Paper
 No. _____ to charge/credit DEPOSIT ACCOUNT
 No. _____ for following:

<input type="checkbox"/> All Fees
<input type="checkbox"/> 1.16 Fees (Filing)
<input type="checkbox"/> 1.17 Fees (Processing Ext. of time)
<input type="checkbox"/> 1.18 Fees (Issue)
<input type="checkbox"/> Other _____
<input type="checkbox"/> Credit